ImmunoPrecise Antibodies Ltd. logo
ImmunoPrecise Antibodies Ltd. IPA

Quarterly report 2026-Q3
added 05-16-2026

report update icon

ImmunoPrecise Antibodies Ltd. Financial Statements 2011-2026 | IPA

Annual Financial Statements ImmunoPrecise Antibodies Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 81.3 M 82.4 M - - - - - - - - - -

Shares

33.4 M 25.6 M 24.9 M 19.7 M 16.5 M - - - - - - - - - -

Historical Prices

4.13 5.36 14.9 2.2 2.56 2.33 0.005 0.015 0.315 0.09 0.3 1.06

Net Income

-30.2 M -26.1 M -26.6 M -16.7 M -7.34 M -4.95 M -7.62 M -5.17 M -5.38 M 151 K -31.9 K -62.3 K 69.4 K -95.8 K -276 K

Revenue

24.5 M 24.5 M 20.7 M 19.4 M 17.9 M 14.1 M 10.9 M 5.44 M 2.63 M 1.9 M - - - - -

Cost of Revenue

11 M 12.5 M 9.1 M 8.38 M 6.37 M 6.02 M - - - - - - - - -

Gross Profit

13.5 M 12.1 M 11.6 M 11 M 11.5 M 8.03 M 5.29 M 2.45 M - - - - - - -

EBITDA

- - - - - -1.47 M -4.35 M -4.53 M -1.29 M 277 K -31 K -64.8 K -96 K -79.9 K -206 K

Operating Expenses

- - - - - 12.1 M 11.5 M 7.21 M - - - - - - -

General and Administrative Expenses

14.7 M 15.6 M 15.4 M 15.4 M 1.44 M 8.6 M 8.3 M 6.31 M 2.82 M 997 K 31 K 64.8 K 94.7 K 79.9 K 206 K

All numbers in CAD currency

Quarterly Income Statement ImmunoPrecise Antibodies Ltd.

2026-Q3 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

46.5 M 32.9 M 46.2 M 46.2 M 25.8 M 25.6 M 27.1 M 24.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-3.93 M -21.5 M -3.2 M -2.96 M -2.94 M -26.1 M -4 M -26.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

4.16 M 6.15 M 4.12 M 3.16 M 6.22 M 24.5 M 5.26 M 20.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

1.69 M 2.86 M 1.46 M 1.63 M 3.02 M 12.5 M 2.91 M 9.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

2.46 M 3.3 M 2.66 M 1.53 M 3.2 M 12.1 M 2.36 M 11.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

3.12 M 3.59 M 3.07 M 3.29 M 4.18 M 15.6 M 4.16 M 15.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ImmunoPrecise Antibodies Ltd. IPA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ImmunoPrecise Antibodies Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.